{"entity":{"id":"idea-moon-quality-adjusted-pricing","kind":"idea","name":"Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer","aka":[],"tldr":"If two drugs extend life equally but one makes patients much sicker, the health system should pay less for the sicker one. Build that into how prices are set.","summary":"Health technology assessment uses quality-adjusted life-years in principle, but in oncology practice utilities are poorly measured and toxicity rarely moves the price. The proposal is an explicit tolerability adjustment in pricing and reimbursement: standardised patient-reported tolerability data from trials feed a published formula that discounts the price for excess symptomatic toxicity and time toxicity relative to comparators, with the discount revisited as real-world PRO data accrue.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015)","url":"https://doi.org/10.1200/JCO.2014.57.9334"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-toxicity-qol","b-drug-pricing"],"keyPapers":["paper-di-maio-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A transparent toxicity price adjustment shifts industry investment toward better-tolerated agents and dosing within one product cycle, measurable as declining grade 3+ and PRO-CTCAE severe rates in newly approved drugs.","rationale":"Manufacturers respond to price signals more reliably than to guidance; today the signal on toxicity is close to zero.","test":"A national payer publishes and applies the adjustment for two years; compare submitted tolerability data quality and pipeline dose-optimisation activity against payers without it.","maturity":"speculative","actor":"payer","cost":"small","horizonYears":3},"route":"/ideas/idea-moon-quality-adjusted-pricing/","neighbours":{"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"paper":[{"id":"paper-di-maio-j-clin-oncol","kind":"paper","name":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","route":"/key-papers/paper-di-maio-j-clin-oncol/"}]}}